<DOC>
	<DOC>NCT01386281</DOC>
	<brief_summary>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Julina in clinical practice. A total 100 patients will be recruited and followed 3 years since starting Julina administration.</brief_summary>
	<brief_title>Julina Post-marketing Surveillance for Climacteric Symptoms in Japan</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Patients who received Julina for postmenopausal osteoporosis Patients who are contraindicated based on the product label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Julina</keyword>
	<keyword>Postmenopausal osteoporosis</keyword>
</DOC>